{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FlexPen+NovoLog%C2%AE",
    "query": {
      "intervention": "FlexPen NovoLog®"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 3,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T05:36:46.452Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00773279",
      "title": "Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 1",
        "Diabetes Mellitus, Type 2",
        "Delivery Systems"
      ],
      "interventions": [
        {
          "name": "FlexTouch®",
          "type": "DEVICE"
        },
        {
          "name": "FlexPen®",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 242,
      "start_date": "2008-09",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2017-03-27",
      "last_synced_at": "2026-09-26T05:36:46.452Z",
      "location_count": 65,
      "location_summary": "Burlingame, California • Concord, California • Encino, California + 59 more",
      "locations": [
        {
          "city": "Burlingame",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00773279"
    },
    {
      "nct_id": "NCT03760068",
      "title": "Mylan Insulin Aspart Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "MYL-1601D Product",
          "type": "DRUG"
        },
        {
          "name": "FlexPen NovoLog®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 478,
      "start_date": "2018-11-07",
      "completion_date": "2020-01-17",
      "has_results": true,
      "last_update_posted_date": "2022-02-25",
      "last_synced_at": "2026-09-26T05:36:46.452Z",
      "location_count": 158,
      "location_summary": "Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 125 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Concord",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03760068"
    },
    {
      "nct_id": "NCT00127296",
      "title": "Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and Syringe",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2",
        "Delivery Systems"
      ],
      "interventions": [
        {
          "name": "FlexPen®",
          "type": "DEVICE"
        },
        {
          "name": "vial and syringe",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "40 Years to 99 Years"
      },
      "enrollment_count": 60,
      "start_date": "2005-07",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2017-01-06",
      "last_synced_at": "2026-09-26T05:36:46.452Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00127296"
    }
  ]
}